Ozempic: GLP-1 analogues may reduce the risk of several obesity-related cancers
In addition to their effects on type 2 diabetes, weight loss and colorectal cancer risk, glucagon-like peptide-1 receptor analogues may also act on nine other obesity-related cancers, reports a new study.
Register for free access or login.
Canadian Healthcare Network is an independent online community for Canadian healthcare professionals in medicine and pharmacy. It is the online home of the Medical Post and Pharmacy Practice + Business.
Membership is free and allows doctors, pharmacists, nurses and many others to get the latest breaking news, updates on clinical guidelines and read (and even write) commentary from your healthcare peers.